REVIEW PAPER
A practical algorithm management of patients with benign prostatic hyperplasia
 
More details
Hide details
1
Department of Health Sciences, Jan Kochanowski Świętokrzyska Akademy, Kielce, Poland
CORRESPONDING AUTHOR
Sławomir Dutkiewicz   

Department of Health Sciences, Jan Kochanowski Świętokrzyska Akademy, Avenue IX Wieków Kielc 19, 25-317 Kielce, Poland.
 
J Pre Clin Clin Res. 2008;2(2):118–121
KEYWORDS
ABSTRACT
Benign prostatic hyperplasia (BPH) is a progressive disorder and a common occurrence in aging men, characterized by increased risk of acute urinary retention (AUR) and which may eventually require surgery due to enlargement of the prostate. The treatment of BPH is a choice between no treatment (watch-and-wait scenario), various surgical procedures, and pharmacotherapy in the majority of cases (>80%). Pharmacotherapy of BPH is based on two concepts, i.e. fi rstly, that alpha–adrenergic blockade reduces smooth muscle tone in the prostate and bladder neck, and secondly that 5 alpha–reductase inhibition causes atrophy of prostate epithelium. Studies have shown that both classes of drugs used as monotherapy produced improvements in patients symptoms. Combination therapy of those drugs is most appropriate in men who are symptomatic, are at high risk of progression of enlarged of prostate (EP), and produced improvements in patients with BPH (relief of voiding symptoms, improvement in urinary fl ow and quality of life). Surgical treatment should be considered for patients with progressive disease and complications of BPH, and who present worsening of symptoms not adequately controlled by medical therapy. This article discusses diagnosis and treatment strategies for BPH and proposes a practical algorithm for treatment based on available literature data and the author’s clinical experience.
 
REFERENCES (35)
1.
Jacobsen SJ, Jacobsen D J, Girman C J, Roberts R, Rhodes T, Lieber MN: Natural history of prostatism: risk factors acute urinary retention. J Urol 1997, 158, 481-487.
 
2.
Abrams P: Windows of change: BPH, BPE, BPO or BOO? Be specifi c! Urol Int 1996, 3(2), 10-11.
 
3.
Dutkiewicz S: Health of Man. Urinary and sexual tract. Amedic, Warsaw 2002.
 
4.
Macfarlane GJ, Sagnier PP, Richard F, Teillac P, Botto H, Boyle P: Determinants of treatment – seeking behaviour for urinary symptoms in older men. Br J Urol 1995, 76, 714-718.
 
5.
Dutkiewicz S: Effi cacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 2001, 32, 423-432.
 
6.
Gades NM, Jacobson S J, Girman CJ, Roberts R O, Lieber MM, Jacobsen SJ: Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 2005, 95, 549-553.
 
7.
Roehrborn CG: Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998, 51, 19-22.
 
8.
Kowakami J, Nickiel JC: Acute urinary retention and surgery for benign prostatic hyperplasia: the patients perspective. Can J Urol 1999, 6, 819-822.
 
9.
Choong S, Emberton M: Acute urinary retention. BJU Int 2000, 85, 186-201.
 
10.
Roberts RO, Jacobsen S J, Jacobsen DJ, Rhodes T, Girman CJ, Lieber MM: Longitudinal changes in peak urinary fl ow rates in a community based cohort. J Urol 2000, 163, 107-113.
 
11.
Dutkiewicz S: Benign Prostatic Hyperplasia (BPH). What are the factors which determine pharmacologic versus surgical approach? Legraf, Warsaw 1996.
 
12.
Board EAU Guidelines Offi ce: EAU Guidelines, Arnhem 2005.
 
13.
Djavan B, Chapple C, Milani S, Marberger M: State of the art on the effi cacy and tolerability of alpha 1-adrenoceptor antagonist in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004, 64, 1081-1088.
 
14.
Roehrborn C G, Siegel R L: Safety and effi cacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebocontrolled studies. Urology 1996, 48, 406-415.
 
15.
Roehrborn CG.: Effi cacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia; a randomized, placebo-controlled trial. Urology 2001, 58, 953-959.
 
16.
Dutkiewicz S: Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up. Int Urol Nephrol 2004, 36, 169-173.
 
17.
Radziwszewski P, Kozłowski R, Dobroński P: Nietrzymanie moczu u chorych na łagodny rozrost stercza. Przegl Urol 2007, 3, 43, 63-68.
 
18.
Clark RV, Herman DJ, Cunningham GR, Wilson TH, Morril BB, Hobbs S: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 2004, 89, 2179-2184.
 
19.
Andriole GL, Kirby R: Safety and tolerability of the dual 5 alpharedcutase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003, 44, 82-88.
 
20.
McConnell J D, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J: The eff ect of fi nasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338, 557-563.
 
21.
Baldwin KC, Ginsberg PC, Harkaway RC: Discontinuation of alphablockade after initial treatment with fi nasteride and doxazosin for bladder outlet obstruction. Urol Int 2001, 66, 84-88.
 
22.
Barkin J, Guimaraes M, Jacobi G, Pushkar G, Taylor S, van Vierssen Trip OB (SMART-1 Investigator Group): Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol 2003, 44, 461-466.
 
23.
Kaplan SA: Benign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful for Primary Care. Vol. 1, No. 1,.
 
24.
Weil Medical College of New York University, New York 2006.
 
25.
Roehrborn C, Heaton J: Medical management for BPH: the role of combination therapy. Eur Urol Suppl 2003, 5, 12, 716-721.
 
26.
Marberger M. The MTOPS study: new fi ndings, new insights and clinical implications for the management of BPH. Eur Urol Suppl 2006, 5, 628-633.
 
27.
Kaplan S A, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM, for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: Combination therapy with doxazosin and fi nasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and baseline total prostate volume of 25 ml or greater. J Urol 2006, 175, 217-221.
 
28.
Dutkiewicz S: Wyniki długotrwałego leczenia skojarzonego doksazosyną i fi nasterydem chorych na łagodny rozrost stercza po pięcioletniej monoterapii doksazosyną. Studia Medyczne Akademii Świętokrzyskiej 2007, 7, 19-24.
 
29.
Dutkiewicz S: Proba leczenia skojarzonego tamsulosyną i fi nasterydem (3 lata) chorych na łagodny rozrost stercza. Lek w Polsce 2007, 17(4), 61-64.
 
30.
Dutkiewicz S, Witeska A.: Leczenie skojarzone (3 lata) doksazosyną i fi nasterydem po pięcioletniej monoterapii doksazosyną chorych na łagodny rozrost stercza (BPH). Problemy Lekarskie 2004, 5/6, 155- 157.
 
31.
Choi B, Tabatabaei S, Bachmann A, Collins E, de la Rosette J, Sancha FG, Muir G, Reich O, Woo H: GreenLight HPS 120-W laser for BPH: Comparative complications and technical recommendations. Eur Urol Suppl 2008, 7, 384-392.
 
32.
Dutkiewicz S, Fortuna M: Wyniki leczenia operacyjnego u chorych na łagodny rozrost stercza ze wskazań bezwzględnych. Urol Pol 2008, 61, 1, 45-47.
 
33.
Helfand B, Mouli S, Dedhia R, McVary KT: Management of lower urinary tract symptoms secondary to benign prostatic hyperplasia with open prostatectomy: results of a contemporary series. J Urol 2006, 176, 2597-2561.
 
34.
Muir G, Sancha F G, Bachmann A, Choi B, Collins E, de la Rosette J, Reich O, Tabatabaei S, Woo H: Techniques and training with greenlight HPS 120-W laser therapy of the prostate: position paper. Eur Urol Suppl 2008, 7, 370-377.
 
35.
Woo H, Reich O, Bachmann A, Choi B, Collins E, de la Rosete J, Sancha FG, Muir G, Tabatabaei S: Outcome of greenlight HPS 120-W laser therapy in specifi c patient populations: those in retention, on anticoagulants and with large prostates (>80ml). Eur Urol Suppl 2008 7, 378-383.
 
eISSN:1898-7516
ISSN:1898-2395